Contact   |    Careers   |    Employees   |    Physicians

Cancer Center


 
 
 

Departments

 
 
 

Cancer Center - Clinical Trials

Oncology Research Office

What is a Clinical Trial?

Clinical trials are used to test, measure, and learn more about the effectiveness and risks of new treatments. After researchers explore experimental treatments in the laboratory, those with the most promising results move into clinical trials.

What are the benefits?

Participants gain access to new treatments before they are widely available, and help others by contributing to medical research that could lead to new breakthroughs.

Who can join a trial?

Participants must qualify based on specific guidelines. Some trials seek those with illnesses or conditions being studied, others need healthy participants.

How are people protected?

Trials are designed to protect participants and keep them safe. Risks and potential benefits are carefully explained, and participants may withdraw at any time. Ethical and legal codes governing medical practice apply to clinical trials, and most are federally regulated. An independent committee of physicians, statisticians, community advocates, and others provide approval and ongoing review to protect the rights of participants. 

Clinical trials give our community access to the best research and next level of care. A recent commendation from the Commission on Cancer made particular note of the number of patients Sibley places in trials.

Please contact Jackie Lobien at (301) 896-3122 or by email jlobien1@jhmi.edu to learn about the clinical trials offered at Sibley.

 

Open Protocol Information

Updated October 1, 2012



Breast Cancer  

NCIC CTG MA.32: A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
 
NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
 
NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus   Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
 
S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
 
WRAMC 07-20029: A Prospective, Randomized, Single-Blinded, Multi-Center Phase II Trial of the HER2/neu Peptide GP2 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2+ OR the Modified HER2/neu Peptide AE37 + GM-CSF Vaccine versus GM-CSF alone in HLA-A2- Node-Positive and High Risk Node-Negative Breast Cancer Patients to Pre
 

Gastrointestinal Cancer  

CALGB 80702:  A Phase III trials of 6 versus 12 treatment of Adjuvant Treatment of Adjuvant  Folfox plus Celecoxib or Placebo for patient with Resected Stage III Colon Cancer.
 

Genitourinary Cancer  

J0874 _ I 150709:  A Phase I study of the mTOR inhibitor Temsirolimus in combination with the HDAC inhibitor Vorinostat in patients with metastatic prostate cancer. 
 
NA_00049775: Phase I/II study of safety and efficacy of Muscadine Plus (MDX) in men with prostate cancer: A randomized dose-finding study of the effects of two doses of MPX capsule on rising prostate-specific antigen in men following initial therapy for prostate cancer 
 
NA_00046780: Efficacy and Safety of oral Kanglaite (KLTc) Gelcap in Men with Prostate Cancer: Randomized, Dose-Ranging Study of the Effects of KLTc Gelcap (3 or 6 capsules four times/day) on Prostate Specific Antigen (PSA) Doubling Time Among Men with Rising PSA Level

Gynecologic Cancer  

GOG 0212: A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or CT-2103 (IND# 70177) Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
 
GOG 0249: A Phase III Trial Of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin In Patients With High-Risk, Early Stage Endometrial Cancer
 
GOG 0258: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
 
GOG 0262: A Randomized Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin with or without Concurrent and Consolidation Bevacizumab (NSC #704865, IND #7921) in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer
 
GOG 0263: A Randomized Phase III Clinical  Trial of  Adjuvant Radiation Versus Chemoradiation  In Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy. 
 
RTOG 0724:  A Phase III Randomized study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without  Adjuvant Chemotherapy In High-Risk Patient With Early-Stage Cervical Carcinoma Following Radical Hysterectomy 


Kidney Cancer

CALGB 90802: A Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors  
 

Lung Cancer  

ECOG E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)
 
SWOG S0819: A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
 
ECOG 5508: Randomized Phase III Study of Maintenance Therapy with Bevacizumab,     Pemetrexed, or a combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC 
 
CALGB 30607:  A Randomized Phase III, Double- Blind Placebo-Controlled trial of Sunitinib (  NSC# 736511, IND # 74019) As Maintenance Therapy in Non-Progressing Patients Following An Initial Four Cycles Of Platinum-Base Combination Chemotherapy In Advance, Stage IIIB/IV Non-Small Cell Lung Cancer
 

Leukemia/Lymphoma  

CALGB 50303: A Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-cell Lymphomas
 

Melanoma  

ECOG 1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α- 2b for Resected High-Risk Melanoma 
 
 
© Copyright 2013 Sibley Memorial Hospital